Clinical trial NCT04739995: Cost-utility and Physiological Effects of LDN in Patients With Fibromyalgia
Official title: 12-month Randomized, Double-blind, Placebo-controlled, Pharmacological Clinical Trial to Evaluate the Effectiveness, Cost-utility and Neurobiological Effects of Low-dose Naltrexone in Patients With Fibromyalgia (INNOVA Project)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE4
Conditions: Randomized Controlled Trial
Lead sponsor: Fundació Sant Joan de Déu
Sponsor class: OTHER
Collaborators: name: Carlos III Health Institute
First posted: 2021-02-05
Enrollment: 99
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Double-blind, randomized controlled trial
Primary purpose: TREATMENT

Brief summary: Background: Low-dose naltrexone (LDN) may be useful in managing the pathologies that alter inflammatory markers, such as Crohn's disease or fibromyalgia (FM). The anti-inflammatory effect of LDN should be produced through the inhibition of Toll-like receptor 4 activity expressed in the membrane of various immune system cells (e.g. microglia). Conversely, due to a rebound effect, LDN could exercise an analgesic effect that strengthens the endogenous inhibitory system. According to this hypothesis, the low-intensity and intermittent blocking of the opioid receptors generated by LDN should induce a compensatory mechanism that should facilitate an increase in the production of endogenous opioids and greater sensitivity of the system to their effects. To date, the effects of LDN in patients with FM have been evaluated through crossover studies that have yielded promising results. Given that the studies conducted up to now have had small sample sizes and crossover designs, and given that there are still no studies in which its potential cost-utility is assessed, studies with greater methodological rigor and larger samples are necessary to confirm the effectiveness of LDN in FM.

Jointly evaluating the effectiveness and cost-utility, the changes in metabolites in certain areas of the brain, and systemic inflammatory markers potentially linked to the etiopathogenesis of FM, should allow us to gain a more detailed knowledge of the neurobiological mechanisms underlying the effectiveness of LDN in this population.

Objectives: To evaluate the effectiveness and safety of LDN in patients with FM and analyse its cost-utility both from the government and the healthcare perspective at 1-year follow-up. Brain metabolites and systemic inflammatory biomarkers will be included to evaluate neurobiological mechanisms behind LDN therapeutic effects.

Design: Randomized, Controlled Trial. Centre: Parc Sanitari Sant Joan de Déu (St. Boi de Llobregat, Spain). Participants: 120 patients with FM will be randomly assigned to LDN (4.5mg/day) or placebo.

Main outcome measure: Pain severity using Ecological Momentary Assessment. Secondary outcomes: functionality, affective symptoms, fibrofog, quality of life. Costs and QALYs will be also calculated. Biomarkers: 50% of the patients will be scanned at baseline and at week 12 for changes in brain metabolites related to neuroinflammation and central sensitization. Immune-inflammatory markers in serum will also be evaluated.

Detailed description: Low-dose Naltrexone (LDN): A potential treatment for fibromyalgia (FM)

Naltrexone is an opioid antagonist used for treating opiate and alcohol dependency that blocks the mu receptors and, to a lesser extent, the delta-opioid receptors. There is growing evidence that naltrexone administered in very low doses (i.e. low-dose naltrexone, LDN) -approximately 1/10 of the usual dose, between 1.5-5 mg vs. 50 mg/day- may be useful in managing the various pathologies that alter inflammatory markers, such as Crohn's disease, multiple sclerosis and FM.

The anti-inflammatory effect of naltrexone should be produced through the inhibition of TLR-4 (Toll-like receptor 4) activity expressed in the membrane of various immune system cells (e.g. microglia, macrophages). Conversely, due to a "rebound effect", LDN could exercise an analgesic effect that strengthens the endogenous inhibitory system. According to this hypothesis, the low-intensity and intermittent blocking of the opioid receptors generated by LDN should induce a compensatory mechanism that should facilitate an increase in the production of endogenous opioids and greater sensitivity of the system to their effects. To date, the effects of LDN in patients with FM have only been evaluated through crossover pilot studies and have always produced highly promising results. Thus, in the first study conducted with LDN in FM (N= 10), ameliorations in the daily pain, stress and fatigue levels were observed. In the same vein, in a posterior study (N= 31), significant improvements (vs. Placebo) in daily pain (28% vs. 18%), satisfaction with life and mood were also observed. In another single-blind crossover study (N= 8) the pre and post changes in the levels of cytokines in plasma were evaluated over 8 weeks, with reductions in a wide range of inflammatory markers being observed (e.g. IL-1, sIL-1ra, IL-6, IL-10, TNF-alpha), as well as changes in the levels of pain (-15%) and FM symptoms (-18%). Given that the studies conducted up to now had reduced sample sizes and crossover designs, and given that there are still no studies in which its potential cost-utility is assessed, studies with greater methodological rigor and larger samples are necessary to confirm the clinical effectiveness of LDN in FM. Jointly evaluating the efficacy and cost-utility analyses, the changes in metabolites (i.e. Glu) in certain areas of the brain, and systemic inflammatory markers potentially linked to the etiopathogenesis of FM, should allow us to gain a more detailed knowledge of the neurobiological mechanisms underlying the effectiveness of LDN in this population. The INNOVA project will enable all these factors to be evaluated for the first time.

Eligibility criteria: General Inclusion Criteria:

* Female between 18 and 70 years old
* Patients diagnosed of FM according to ACR 2016 criteria
* Chronic widespread pain for at least 6 months ranked ≥ 4 out of 10;
* Understand Spanish;
* Written informed written consent;

General Exclusion Criteria:

* Treatment with opiates in last 3 months;
* Diagnosis of severe medical/psychiatric disorders (e.g. cancer, severe depression, psychotic disorder, schizophrenia);
* Being pregnant (or planning a pregnancy during the study period) or breastfeeding;
* Known allergy to naltrexone or naloxone;
* Hematological disorders;
* Abnormal hepatic function;
* Taking anticoagulant medication;
* Alcohol consume during the study period
* Participation in other clinical trials;

Additional inclusion criteria for biomarker sub-study:

Right-handed (for the neuroimaging tests)

Additional exclusion criteria for biomarker sub-study:

Comorbid rheumatologic illnesses (e.g. rheumatoid arthritis, lupus); fever (\> 38ºC) or infection in the last 2 weeks; vaccination in the last 4 weeks; Take drugs with anti-inflammatory effects in the 72h prior to blood / neuroimaging; taking cortisone or anti-cytokine therapy; needle phobia; inability to be scanned (due to claustrophobia, metal implants, pacemakers, etc.); Body Mass Index (BMI) \> 36 kg/m2; consumption of \> 8 units of caffeine per day; smoking \> 10 cigarettes/day; acute pain not-related to FM on the day of the scan (e.g. headache, back pain).

Primary outcomes:
measure: Pain intensity
timeFrame: Through study completion, an average of 1 year
Secondary outcomes:
measure: Revised Fibromyalgia Impact Questionnaire (FIQR)
timeFrame: Through study completion, an average of 1 year
measure: Depression Anxiety Stress Scale (DASS-21)
timeFrame: Through study completion, an average of 1 year
measure: Multidimensional Inventory of Subjective Cognitive Impairment (MISCI)
timeFrame: Through study completion, an average of 1 year
Other outcomes:
measure: EuroQoL (EQ-5D-5L)
timeFrame: Through study completion, an average of 1 year
measure: Client Service Receipt Inventory (CSRI)
timeFrame: Through study completion, an average of 1 year
measure: Patient Global and Specific Impression of Change (PGIC/PSIC)
timeFrame: Through study completion, an average of 1 year
measure: ACTTION AE
timeFrame: Through study completion, an average of 1 year
measure: The Pain Monitor® app
timeFrame: Through study completion, an average of 1 year
measure: Socio-demographic questionnaire
timeFrame: Baseline
measure: 12-item WHODAS 2.0
timeFrame: Baseline
measure: Generalized Anxiety Disorder 7-item scale (GAD-7)
timeFrame: Baseline
measure: Fibromyalgia Survey Diagnostic Criteria (FSDC)
timeFrame: Baseline
Locations:
city: Sant Boi De Llobregat
country: Spain
facility: Parc Sanitari Sant Joan de Déu (PSSJD)
state: Barcelona
Study officials:
affiliation: Fundació Sant Joan de Déu
name: Juan V. Luciano, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Colomer-Carbonell A, Sanabria-Mazo JP, Hernandez-Negrin H, Borras X, Suso-Ribera C, Garcia-Palacios A, Muchart J, Munuera J, D'Amico F, Maes M, Younger JW, Feliu-Soler A, Rozadilla-Sacanell A, Luciano JV. Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study). BMJ Open. 2022 Jan 6;12(1):e055351. doi: 10.1136/bmjopen-2021-055351.